Literature DB >> 2827942

Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure.

E L Schiffrin1.   

Abstract

1. Binding sites for atrial natriuretic peptide (ANP) with a specificity similar to that of vascular ANP receptors have been demonstrated previously in human platelets. The density of these binding sites for ANP on platelets is decreased after increased dietary sodium intake, when plasma ANP levels increase. ANP-binding sites were investigated in patients with severe congestive heart failure (CHF), a condition in which there is an increase in the concentration of ANP in plasma. 2. In 24 patients with a clinical diagnosis of functional class III-IV CHF, plasma ANP (90.3 +/- 13.4 fmol/ml, mean +/- SEM) was significantly higher (P less than 0.001) than in 16 age-matched patients without cardiac disease (15.4 +/- 2.0 fmol/ml). The density of ANP-binding sites on platelets was significantly lower (P less than 0.01) in the 24 CHF patients (6.3 +/- 0.8 fmol/10(9) cells) than in the non-cardiac patients (11.8 +/- 1.4 fmol/10(9) cells). There was no significant difference in affinity of the ANP-binding sites between both groups. There was a significant non-linear inverse correlation of the density of ANP-binding sites on platelets with plasma ANP concentration. These results could not be explained by prior receptor occupancy secondary to the elevated concentration of circulating ANP. 3. In conclusion, ANP-binding sites on platelets are decreased in patients with severe CHF and with significantly elevated concentration of ANP in plasma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827942     DOI: 10.1042/cs0740213

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  17 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 2.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

3.  Particulate guanylate cyclase and adenylate cyclase activities after activation with various agents in rabbit platelets. An ultracytochemical study.

Authors:  A Spreca; M G Rambotti; R Donato
Journal:  Histochem J       Date:  1991-03

4.  Streptozotocin-induced diabetes impairs G-protein linked signal transduction in vascular smooth muscle.

Authors:  Shehla Hashim; Yi Yong Liu; Rui Wang; Madhu B Anand-Srivastava
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

Review 5.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 6.  Harnessing the therapeutic potential of atrial natriuretic peptide.

Authors:  A G Jardine; D B Northridge; J M Connell
Journal:  Klin Wochenschr       Date:  1989-09-01

7.  Effect of atrial natriuretic factor on platelet function in whole blood ex-vivo in man.

Authors:  C C Lang; C S Lau; J J Belch; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases.

Authors:  Johanne Tremblay; Richard Desjardins; David Hum; Jolanta Gutkowska; Pavel Hamet
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

9.  Renal and hormonal effects and tolerance of an ANP analogue in healthy man.

Authors:  H Eiskjaer; M Schmiegelow; B Jespersen; I N Tietze; J D Jensen; S S Sørensen; K Thomsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.